Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 44 of 44 results for durvalumab

  1. Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)

    Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.

    Technology appraisal guidance
    Published
    10 January 2024
    View recommendations

    Sections for TA944

  2. Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA798)

    Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.

    Technology appraisal guidance
    Published
    22 June 2022
    View recommendations

    Sections for TA798

  3. More than 400 people could benefit from life-extending advanced lung cancer treatment after it was recommended for routine use on the NHS

    Durvalumab recommended as an option for treating non-small-cell lung cancer (NSCLC)

    News
    Published
    16 May 2022

  4. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.

    Technology appraisal guidance
    Published
    28 April 2021
    View recommendations

    Sections for TA692

  5. Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) (TA662)

    NICE is unable to make a recommendation on durvalumab (Imfinzi) in combination for untreated extensive-stage small-cell lung cancer in adults because AstraZeneca withdrew its evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    25 November 2020

    Sections for TA662

  6. Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)

    Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    2 September 2020
    View recommendations

    Sections for TA645

  7. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA578)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA798.

    Technology appraisal guidance
    Published
    1 May 2019

  8. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    In development [GID-TA11041] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]

    Discontinued [GID-TA10394]

    Technology appraisal guidance
    Discontinued

  10. Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

    Awaiting development [GID-TA10748] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]

    Discontinued [GID-TA10315]

    Technology appraisal guidance
    Discontinued

  12. Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]

    Discontinued [GID-TA10324]

    Technology appraisal guidance
    Discontinued

  13. Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]

    Discontinued [GID-TA10186]

    Technology appraisal guidance
    Discontinued

  14. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued [GID-TA10318]

    Technology appraisal guidance
    Discontinued

  15. Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]

    Discontinued [GID-TA10474]

    Technology appraisal guidance
    Discontinued

  16. Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]

    Discontinued [GID-TA10473]

    Technology appraisal guidance
    Discontinued

  17. Durvalumab with tremelimumab for treating recurrent or metastatic squamous-cell head and neck cancer [ID1558]

    Discontinued [GID-TA10875]

    Technology appraisal guidance
    Discontinued

  18. Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]

    Discontinued [GID-TA10617]

    Technology appraisal guidance
    Discontinued

  19. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736

    Awaiting development [GID-TA11076] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  20. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5097]

    Awaiting development [GID-TA11011] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  21. Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080]

    Awaiting development [GID-TA10967] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  22. Durvalumab (Imfinzi) with bevacizumab (Avastin) for high-risk adjuvant hepatocellular carcinoma [ID6146]

    Awaiting development [GID-TA11222] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  23. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development [GID-TA11281] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  24. Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]

    Discontinued [GID-TA10963]

    Technology appraisal guidance
    Discontinued

  25. Durvalumab with tremelimumab for untreated EGFR- and ALK-negative locally advanced and metastatic non-small-cell lung cancer [ID1538]

    Discontinued [GID-TA10422]

    Technology appraisal guidance
    Discontinued

  26. Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]

    Discontinued [GID-TA10633]

    Technology appraisal guidance
    Discontinued

  27. Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073]

    Awaiting development [GID-TA10959] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  28. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development [GID-TA11019] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  29. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]

    Awaiting development [GID-TA11214] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  30. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development [GID-NG10404] Expected publication date: TBC

    NICE guideline
    In development

  31. Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]

    Discontinued [GID-TA10616]

    Technology appraisal guidance
    Discontinued

  32. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development [GID-TA10911] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  33. Treatments for non-small-cell lung cancer [ID6234]

    In development [GID-TA11289] Expected publication date: TBC

    Technology appraisal guidance
    In development

  34. Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer (Review of TA662) [ID6404]

    Awaiting development [GID-TA11515] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  35. Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

    In development [GID-TA10783] Expected publication date: TBC

    Technology appraisal guidance
    In development

  36. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable TS ID 11989

    Awaiting development [GID-TA11517] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  37. Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]

    Awaiting development [GID-TA11440] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  38. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development [GID-TA11161] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  39. Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma ID2725

    In development [GID-TA10571] Expected publication date: TBC

    Technology appraisal guidance
    In development

  40. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer ID6317

    In development [GID-TA11340] Expected publication date: TBC

    Technology appraisal guidance
    In development

  41. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6428

    Awaiting development [GID-TA11538] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  42. Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220]

    In development [GID-TA11197] Expected publication date: TBC

    Technology appraisal guidance
    In development

  43. Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]

    In development [GID-TA11174] Expected publication date: 16 October 2024

    Technology appraisal guidance
    In development

  44. Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]

    Awaiting development [GID-TA11115] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development